+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Thrombin Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4986953
  • Report
  • February 2020
  • Region: Global
  • 120 pages
  • Mordor Intelligence
UP TO OFF
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Baxter
  • Bayer
  • CSL
  • GE Healthcare
  • Hualan Biological
  • Johnson & Johnson
  • MORE
The thrombin market studied was projected to grow with a CAGR of nearly 4.3% over the forecast period. The major factor attributing to the growth of the market is the increase in the incidence of trauma and the increasing number of accidents, and the number of surgeries and the increasing usage of thrombin in clotting the blood. According to the report published by the Ministry of Road Transport and Highways, India, a total of 4,67,044 road accidents have been reported by States and Union Territories in the year 2018, claiming 1,51,417 lives and causing injuries to 4,69,418 persons. Furthermore, increasing incidence of inherited blood clotting disorders like hemophilia, Von Willebrand Disease etc. As the number of patients increases the demand for the thrombin grows. However, the strict regulation policies is the drawback of market growth.

Key Market Trends

Bovine Thrombin Segment is Dominating the Thrombin Market.
  • Bovine thrombin is the most regularly used products in the market. The segment is expected to continue to dictate the market during the forecast period due to economical prices. Rising adoption of bovine-based products in various research and diagnostic applications is also boosting the market.
  • The other factors that play a crucial role in the growth of the segment are the increasing incidence of accidents, trauma, and other inherited blood clotting diseases. According to the World Health Organization, 1.35 million people die each year as a result of road traffic crashes, between 20 and 50 million more people suffer non-fatal injuries, with many incurring a disability as a result of their injury.
North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of accidents and trauma in the region, and the surge in the prevalence of inherited blood disorders established healthcare infrastructure are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth. In this region the United States has the maximum share due to supportive healthcare policies, the high number of patients, and a developed healthcare market. According to Association for Safe International Road Travel, over 37,000 people die in road crashes each year, an additional 2.35 million are injured or disabled, over 1,600 children under 15 years of age die each year, in the United States. As per the statistics, the increasing patient pool and increasing disposable revenue in this country boosts the market growth of the region.

Competitive Landscape

The Thrombin market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Pfizer Inc., Johnson & Johnson Services Inc., Mallinckrodt Pharmaceuticals, Shanghai RAAS blood products co., Ltd, Japan Blood Products Organization, Mochida Pharmaceutical Co., Ltd., Octapharma, Bayer, Baxter, GE Healthcare.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Baxter
  • Bayer
  • CSL
  • GE Healthcare
  • Hualan Biological
  • Johnson & Johnson
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Adoption of Thrombin in Surgeries
4.2.2 Surge in the Incidence of Inherited Blood Clotting Disorders
4.3 Market Restraints
4.3.1 Strict Regulatory Guidelines
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Product
5.1.1 Bovine Thrombin
5.1.2 Human Thrombin
5.1.3 Recombinant Thrombin
5.2 By Dosage Form
5.2.1 Powder Forms
5.2.2 Solution Forms
5.3 By End-User
5.3.1 Hospitals
5.3.2 Diagnostics Centers & Clinics
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 Johnson & Johnson
6.1.3 Baxter
6.1.4 Shanghai RAAS blood products co., Ltd
6.1.5 GE Healthcare
6.1.6 Hualan Biological
6.1.7 Octapharma
6.1.8 Bayer
6.1.9 CSL

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Pfizer Inc.
  • Johnson & Johnson
  • Baxter
  • Shanghai RAAS blood products co., Ltd
  • GE Healthcare
  • Hualan Biological
  • Octapharma
  • Bayer
  • CSL
Note: Product cover images may vary from those shown
Adroll
adroll